注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
C4 Therapeutics Inc是一家生物制药公司。该公司致力于利用人体对蛋白质水平的自然调节来开发备选药物,以针对和破坏引起疾病的蛋白质,从而治疗癌症、神经退行性疾病和其他疾病。该公司提供的技术平台,即面向目标的蛋白质降解优化剂(TORPEDO),合成一类新型的小分子蛋白质降解物,旨在降解引起疾病的蛋白质,其中包括先前被认为不可食用的目标。该公司的主要备选产品CFT7455是针对多发性骨髓瘤(MM)、外周T细胞淋巴瘤(PTCL)和套细胞淋巴瘤(MCL)的IKZF1/3的口服生物可利用降解剂。该公司也正在开发CFT8634,这是一种被称为溴结构域的口服生物可利用的蛋白质靶标降解物,含9(BRD9),用于治疗滑膜肉瘤和SMARCB1缺失的实体瘤。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Andrew J. Hirsch | 51 | 2020 | CEO, President & Director |
Kenneth C. Anderson | 71 | 2015 | Co-Founder, Independent Director & Member of Scientific Advisory Board |
Donna Roy Grogan | 66 | 2022 | Independent Director |
Laura Bessen | - | 2022 | Independent Director |
Bruce L. Downey | 76 | 2015 | Chairman & Lead Independent Director |
Nathanael S. Gray | - | 2016 | Co-Founder & Member of Scientific Advisory Board |
Christopher J. Kirk | 50 | 2016 | Member of Scientific Advisory Board |
Glenn Russell Dubin | 66 | 2021 | Independent Director |
Ross L. Levine | 51 | 2017 | Member of Scientific Advisory Board |
Randi Isaacs | 67 | - | Member of Clinical Advisory Board |
Scott A. Armstrong | - | 2017 | Member of Scientific Advisory Board |
Christopher J. Bowden | 62 | - | Member of Clinical Advisory Board |
Hagop Youssoufian | 66 | 2023 | Member of Clinical Advisory Board |
Malcolm S. Salter | 83 | 2015 | Independent Director |
Utpal Koppikar | 52 | 2022 | Independent Director |
Beni B. Wolf | - | - | Member of Clinical Advisory Board |
Ryan B. Corcoran | - | 2019 | Member of Scientific Advisory Board |
Owen P. Hughes | 49 | 2023 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核